Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atreca, Inc.BCEL · Entity 91940 | Director | June 13, 2023 | June 15, 2023 |
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | Director | January 07, 2026 | January 09, 2026 |
| Clovis Oncology, Inc.CLVS · Entity 122635 | See Remarks | November 01, 2022 | November 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atreca, Inc.
Report date June 13, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2023-06-12 | Direct | 12,000 |
Reported balance
After 2023-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-13 · Grant · Acquired 12,000 · Balance 12,000 F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.
CERO THERAPEUTICS HOLDINGS, INC.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2036-01-06 | Direct | 690,900 |
Reported balance
After 2026-01-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 690,900 · Balance 690,900 |
Clovis Oncology, Inc.
Report date November 01, 2022 · Filed November 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 113,327 |
Reported balance
After 2022-11-01 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2022-11-01 · Exercise / conversion · Acquired 3,749 · Balance 113,327 F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 111,419 |
Reported balance
After 2022-11-02 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2022-11-02 · Sale · Disposed 1,908 · Balance 111,419 F2: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $ 0.9621 to $9.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 116,044 |
Reported balance
After 2022-11-01 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2022-11-01 · Exercise / conversion · Acquired 4,625 · Balance 116,044 F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 113,691 |
Reported balance
After 2022-11-02 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2022-11-02 · Sale · Disposed 2,353 · Balance 113,691 F2: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $ 0.9621 to $9.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,750 |
Reported balance
After 2022-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-01 · Exercise / conversion · Disposed 3,749 · Balance 3,750 F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,125 |
Reported balance
After 2022-11-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-01 · Exercise / conversion · Disposed 4,625 · Balance 23,125 F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F5: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3: This transaction was executed in multiple trades at prices ranging from $ 0.9621 to $9.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F5: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2018 Filed Mar 21, 2018 18:54 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 3,437 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-008295 · doc4.xml · derivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,813 Underlying: Common Stock · 3,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F2 · date: On December 19, 2016, the reporting person was granted 55,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on December 19, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F2 · derivative.exercise_date: On December 19, 2016, the reporting person was granted 55,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on December 19, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F2 · derivative.expiration_date: On December 19, 2016, the reporting person was granted 55,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on December 19, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| March 20, 2018 Filed Mar 21, 2018 18:54 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Tax withholdingCommon Stock | 1,728 | $56.75 | $98,064.00 |
DisclosureSEC source: 0000899243-18-008295 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,789 Read SEC document |
| March 20, 2018 Filed Mar 21, 2018 18:54 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 3,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-008295 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 18:00 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006977 · doc4.xml · derivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Common Stock. F2 · date: On March 27, 2017, the reporting person was granted 10,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F2 · derivative.exercise_date: On March 27, 2017, the reporting person was granted 10,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F2 · derivative.expiration_date: On March 27, 2017, the reporting person was granted 10,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 18:00 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Tax withholdingCommon Stock | 1,260 | $58.43 | $73,621.80 |
DisclosureSEC source: 0000899243-18-006977 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,080 Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 18:00 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-006977 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive one share of Common Stock. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 18:25 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantRestricted Stock Units · Derivative | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006218 · doc4.xml · derivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Common Stock. F3 · derivative.exercise_date: The restricted stock units shall vest as to 25% of the units on March 1, 2019, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.expiration_date: The restricted stock units shall vest as to 25% of the units on March 1, 2019, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 18:25 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $58.43 | $0.00 |
DisclosureSEC source: 0000899243-18-006218 · doc4.xml · derivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: The option shall vest as to 25% of the shares on March 1, 2019, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 16:46 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-029379 · doc4.xml · derivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 13,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F2 · date: On December 19, 2016, the reporting person was granted 55,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on December 19, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F2 · derivative.exercise_date: On December 19, 2016, the reporting person was granted 55,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on December 19, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F2 · derivative.expiration_date: On December 19, 2016, the reporting person was granted 55,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on December 19, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 16:46 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Tax withholdingCommon Stock | 6,910 | $63.80 | $440,858.00 |
DisclosureSEC source: 0000899243-17-029379 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,840 Read SEC document |
| December 20, 2017 Filed Dec 21, 2017 16:46 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 13,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-029379 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| March 27, 2017 Filed Mar 28, 2017 18:48 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-008766 · doc4.xml · derivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Common Stock. F3 · derivative.exercise_date: The restricted stock units shall vest as to 25% of the units on March 1, 2018, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.expiration_date: The restricted stock units shall vest as to 25% of the units on March 1, 2018, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| March 27, 2017 Filed Mar 28, 2017 18:48 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $68.31 | $0.00 |
DisclosureSEC source: 0000899243-17-008766 · doc4.xml · derivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-27 F1 · derivative.exercise_date: The option shall vest as to 25% of the shares on March 1, 2018, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. Read SEC document |
| December 19, 2016 Filed Dec 19, 2016 18:47 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantRestricted Stock Units · Derivative | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-035970 · doc4.xml · derivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Common Stock. F2 · derivative.exercise_date: The restricted stock unit shall vest as to 25% of the units on December 19, 2017, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. F2 · derivative.expiration_date: The restricted stock unit shall vest as to 25% of the units on December 19, 2017, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.